MerLion Pharmaceuticals GmbH   Report issue

For profit Phase 1 Phase 2
Founded: Singapore Singapore (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2007
NCT00492271
First Marketed Drug
2014
finafloxacin (xtoro)
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

MerLion Pharms Gmbh | MERLION PHARMS GMBH

Active Ingredients

Marketed Drugs (1)

finafloxacin (xtoro) (2014)

Drugs in Phase 2 Trials (4)

ciprofloxacin (cipro) (2 trials)

esomeprazole (nexium) (1 trial)

finafloxacin (xtoro) (7 trials)

procaine benzylpenicillin (novocaine) (1 trial)

Drugs in Phase 1 Trials (1)

friulimicin b (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 2)

Cellulitis (Phase 1)

Communicable Diseases (Phase 2)

Dyspepsia (Phase 2)

Gram-Negative Bacterial Infections (Phase 2)

Helicobacter Infections (Phase 2)

Infections (Phase 2)

Pneumonia (Phase 1)

Pyelonephritis (Phase 2)

Skin Diseases, Infectious (Phase 1)

Staphylococcal Skin Infections (Phase 1)

Urinary Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5